Advaxis cuts staff as it seeks partner for troubled cancer vaccine

Advaxis cuts staff as it seeks partner for troubled cancer vaccine

Source: 
Fierce Biotech
snippet: 

Just six weeks after taking the helm of biotech Advaxis, CEO Ken Berlin has launched a search for a partner for its stalled lead axalimogene filolisbac (AXAL) and will scale back trials of the immunotherapy in order to bring earlier stage programs forward. It will also eliminate almost a quarter of its workforce.